ArticleDiagnostics (Basel, Switzerland)2018
Multimodal Discrimination between Normal Aging, Mild Cognitive Impairment and Alzheimer's Disease and Prediction of Cognitive Decline.
Article in Diagnostics (Basel, Switzerland), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 32 citations in OpenAlex.
- Article
- Diagnostic and prognostic multimodal prediction models in Alzheimer's disease: A scoping review.Journal of Alzheimer's disease : JAD · 2025Article
- Profile of non-invasive physical health indicators associated with cognitive performance in Chinese older adults: evidence from the China Health and Retirement Longitudinal Study.BMC public health · 2025Article
- Article
- Tau-PET is superior to phospho-tau when predicting cognitive decline in symptomatic AD patients.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2023Article
- Relationship between parental history of dementia, motor-cognitive and executive function performance in African American women.Journal of the neurological sciences · 2022Article
- Translation, Adaptation and Validation of the Five-Word Test (Test Delle 5 Parole, T5P) in an Italian Sample: A Rapid Screening for the Assessment of Memory Impairment.Geriatrics (Basel, Switzerland) · 2022Article
- Novel characterization of the relationship between verbal list-learning outcomes and hippocampal subfields in healthy adults.Human brain mapping · 2021Article
- Article
- Prediction of Subtle Cognitive Decline in Normal Aging: Added Value of Quantitative MRI and PET Imaging.Frontiers in aging neuroscience · 2021Article
- Word Meaning Contributes to Free Recall Performance in Supraspan Verbal List-Learning Tests.Frontiers in psychology · 2020Article
- Narrative impairment, white matter damage and CSF biomarkers in the Alzheimer's disease spectrum.Aging · 2019Article
- A practical computerized decision support system for predicting the severity of Alzheimer's disease of an individual.Expert systems with applications · 2019Article
- ALTEA: A Software Tool for the Evaluation of New Biomarkers for Alzheimer's Disease by Means of Textures Analysis on Magnetic Resonance Images.Diagnostics (Basel, Switzerland) · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
Alzheimer's Disease (AD) and mild cognitive impairment (MCI) are associated with widespread changes in brain structure and function, as indicated by magnetic resonance imaging (MRI) morphometry and 18-fluorodeoxyglucose position emission tomography (FDG PET) metabolism. Nevertheless, the ability to differentiate between AD, MCI and normal aging groups can be difficult. Thus, the goal of this study was to identify the combination of cerebrospinal fluid (CSF) biomarkers, MRI morphometry, FDG PET metabolism and neuropsychological test scores to that best differentiate between a sample of normal aging subjects and those with MCI and AD from the Alzheimer's Disease Neuroimaging Initiative. The secondary goal was to determine the neuroimaging variables from MRI, FDG PET and CSF biomarkers that can predict future cognitive decline within each group. To achieve these aims, a series of multivariate stepwise logistic and linear regression models were generated. Combining all neuroimaging modalities and cognitive test scores significantly improved the index of discrimination, especially at the earliest stages of the disease, whereas MRI gray matter morphometry variables best predicted future cognitive decline compared to other neuroimaging variables. Overall these findings demonstrate that a multimodal approach using MRI morphometry, FDG PET metabolism, neuropsychological test scores and CSF biomarkers may provide significantly better discrimination than any modality alone.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.